Trv Gp V LLC Makes New $28.37 Million Investment in Maze Therapeutics, Inc. $MAZE

Trv Gp V LLC purchased a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 950,800 shares of the company's stock, valued at approximately $28,371,872. Maze Therapeutics comprises 0.0% of Trv Gp V LLC's investment portfolio, making the stock its 3rd largest position. Trv Gp V LLC owned about 1.72% of Maze Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. TRV GP IV LLC purchased a new stake in shares of Maze Therapeutics in the second quarter valued at about $133,502,907. BlackRock Inc. purchased a new stake in shares of Maze Therapeutics in the second quarter worth approximately $104,525,000. Janus Henderson Group PLC increased its position in Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company's stock worth $130,197,000 after buying an additional 2,390,713 shares during the period. Vanguard Group Inc. grew its position in Maze Therapeutics by 27.1% during the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company's stock worth $70,307,000 after acquiring an additional 362,060 shares during the last quarter. Finally, Alphabet Inc. bought a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $41,435,000.

Insiders Place Their Bets

In related news, CMO Harold Bernstein sold 16,142 shares of Maze Therapeutics stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the sale, the chief marketing officer directly owned 16,142 shares in the company, valued at $445,680.62. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the sale, the insider directly owned 26,250 shares in the company, valued at approximately $717,675. The trade was a 22.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 108,110 shares of company stock valued at $3,057,531 over the last 90 days. 5.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research note on Monday. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. BTIG Research reissued a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Maze Therapeutics has a consensus rating of "Buy" and a consensus price target of $66.00.

Maze Therapeutics Price Performance

Shares of MAZE stock traded down $1.18 during trading on Friday, hitting $27.42. The company had a trading volume of 79,738 shares, compared to its average volume of 643,743. The stock's 50-day moving average price is $28.70 and its 200 day moving average price is $31.93. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The firm has a market capitalization of $1.52 billion, a P/E ratio of -10.88 and a beta of 2.21. Maze Therapeutics, Inc. has a one year low of $13.89 and a one year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.76). Equities analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Maze Therapeutics Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.